Allianz Group progresses towards inclusion with neurotechnology and AI

Oliver Bäte Chairman of the Board of Management of Allianz SE (CEO) Allianz SE
Oliver Bäte Chairman of the Board of Management of Allianz SE (CEO) - Allianz SE
0Comments

The Allianz Group, a prominent global insurer and asset manager, is making strides in the field of neurotechnology and artificial intelligence to enhance inclusion. The company serves approximately 128 million private and corporate customers across nearly 70 countries. Its offerings include a wide array of insurance services such as property, life, health, assistance services, credit insurance, and global business insurance.

Allianz stands out as one of the largest investors worldwide, managing around 768 billion euros on behalf of its insurance clients. Additionally, its asset management arms—PIMCO and Allianz Global Investors—oversee about 1.9 trillion euros in third-party assets.

The group has integrated ecological and social criteria into its business processes and investment decisions, securing a leadership position in the Dow Jones Sustainability Index within the insurance industry. In 2024, over 156,000 employees contributed to achieving a total business volume of 179.8 billion euros and an operating profit of 16 billion euros for Allianz.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.